Redeye adjusts the short-term estimates downward due to a slightly more challenging business environ...
Gross profit SEK 8.2m (+3% vs. ABGSCe 8.0m) Expects double-digit growth and increasing gross margin ...
Redeye comments on the Q1 report, which offered few surprises.
Redeye considers Arise Q1-figures solid with strong operational cash flow, driven mainly by higher e...
Addvise, en nischförvärvare av medicintekniska bolag, har inlett 2022 med hög förvärvad tillväxt och...
Redeye keeps its fair value range unchanged with Q1 in line with our estimates.
Q1’22 EBITDA of SEK 61m, in line with ABGSCe Production EBITDA SEK 65m above ABGSCe SEK 59m Limited ...
1-2% better than ABGSCe Occupancy rate of 91.1% vs 90.
Redeye comments on Aspire’s Q1-results which came in slightly above expectations driven by strong pe...
Main Markets continue to perform despite a tough market ’23e-’24e EBITA up by 4%, ’22e kept as is Fa...
The CMD added color on Enersense’s plans to expand its print in the renewables value chain.
Stockwik is an M&A compounder, with a focus on acquiring non-cyclical companies with a solid track r...
Positive top line revisions while lowered NOI margin Borrowing terms should improve even with higher...
Estimates up on higher production and oil prices Q1 could mark a turning point Discounts USD 68/bbl...
NAVPS (SEK) flat q-o-q and up 55% y-o-y in Q1’22 Trading at 45% discount to NAVPS Fair value rang...
GM down due to high transportation costs… ...so we lower 2022e GP by 10% Trading at EV/EBIT 9x-5x o...
Organic sales +4.4% y-o-y, adj. EBIT margin 13.2% (11%) Positive EBIT revisions from raised profitab...
Adj. EBITA SEK 267m (+10% vs. Infront cons. 242m) Guides for -20% q-o-q growth in Integrated Solutio...
The Prostatype Genomics Board has proposed a SEK 22.
This morning, HANZA reported its Q1 2022 earnings. Below is our first impressions on the report.
